Stoke Therapeutics completes enrollment in Phase 3 Dravet study

June 30, 2026 8:01 AM

Stoke Therapeutics (Nasdaq: STOK) has completed enrollment of 162 patients into the Phase 3 EMPEROR study evaluating zorevunersen, an investigational ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found